Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incretin hormones: Their role in health and disease
Michael A. Nauck, Juris J. Meier
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. S1, pp. 5-21
Closed Access | Times Cited: 653

Showing 1-25 of 653 citing articles:

Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen, Jesper Lau
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 630
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, et al.
Molecular Metabolism (2018) Vol. 18, pp. 3-14
Open Access | Times Cited: 575
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, et al.
The Lancet (2021) Vol. 398, Iss. 10300, pp. 583-598
Closed Access | Times Cited: 421
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Dominik Dahl, Yukiko Onishi, Paul Norwood, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 534-534
Open Access | Times Cited: 361
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 351
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 317
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Rexiati Ruze, Tiantong Liu, Xi Zou, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 316
Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 292
The carbohydrate-insulin model: a physiological perspective on the obesity pandemic
David S. Ludwig, Louis J. Aronne, Arne Astrup, et al.
American Journal of Clinical Nutrition (2021) Vol. 114, Iss. 6, pp. 1873-1885
Open Access | Times Cited: 223
Inter-organ cross-talk in metabolic syndrome
Christina Priest, Peter Tontonoz
Nature Metabolism (2019) Vol. 1, Iss. 12, pp. 1177-1188
Closed Access | Times Cited: 218
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, et al.
Diabetologia (2022) Vol. 65, Iss. 8, pp. 1251-1261
Open Access | Times Cited: 184
The incretin system in healthy humans: The role of GIP and GLP-1
Jens J. Holst
Metabolism (2019) Vol. 96, pp. 46-55
Open Access | Times Cited: 181
Impact of Gut Microbiota on Host Glycemic Control
Céline Gérard, Hubert Vidal
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 177
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
Amelia D. Dahlén, Giovanna Dashi, Ivan Maslov, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 175
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
Jamy D. Ard, Angela Fitch, Sharon Fruh, et al.
Advances in Therapy (2021) Vol. 38, Iss. 6, pp. 2821-2839
Open Access | Times Cited: 167
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Tim Heise, Andrea Mari, J. Hans DeVries, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 418-429
Closed Access | Times Cited: 166
Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
Juan P. Frías, Michael A. Nauck, Joanna Van, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 6, pp. 938-946
Open Access | Times Cited: 164
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms, Michael E. Christe, Kyla Collins, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 12
Open Access | Times Cited: 150
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Shweta Urva, Tamer Coşkun, Mei Teng Loh, et al.
The Lancet (2022) Vol. 400, Iss. 10366, pp. 1869-1881
Closed Access | Times Cited: 140
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 9, pp. 623-633
Closed Access | Times Cited: 136
Regulation of Postabsorptive and Postprandial Glucose Metabolism by Insulin-Dependent and Insulin-Independent Mechanisms: An Integrative Approach
George Dimitriadis, Eirini Maratou, Aikaterini Kountouri, et al.
Nutrients (2021) Vol. 13, Iss. 1, pp. 159-159
Open Access | Times Cited: 134
Role of the gut–brain axis in energy and glucose metabolism
Hallie Wachsmuth, Savanna N. Weninger, Frank A. Duca
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 4, pp. 377-392
Open Access | Times Cited: 129
Page 1 - Next Page

Scroll to top